PROTACs
PROTAC (PROteolysis-TArgeting Chimera) is a heterobifunctional nanomolecule containing two different ligands, ligand for ubiquitin E3 and ligand for target protein. The two parts are connected by linker to form a "three-unit" polymer, target protein ligand-linker-E3 ligase ligand. Building blocks of PROTAC molecules include PROTAC Linker, Ligand for Target Protein for PROTAC, Ligand for E3 Ligase, E3 Ligase Ligand-Linker Conjugate, Target Protein Ligand-Linker Conjugate, etc.
PROTACs Isoform Specific Products
All Product Categories
-
PROTACs Related Products (1355)
Related Products (1355)
-
Antibodies (1)
-
PROTACs Isoform Comparison
-
SGI-1776-VHL-02
0 ImagesCat. No.: HY-186146CAS No.: 3013618-84-0SGI-1776-VHL-02 is a stereoselective PIM PROTAC degrader. SGI-1776-VHL-02 promotes the ubiquitination and degradation of PIM1, PIM2 and PIM3. SGI-1776-VHL-02 downregulates c-myc protein levels, induces Apoptosis. SGI-1776-VHL-02 has anti-cancer activity against prostate cancer. SGI-1776-VHL-02 can be used in studies related to prostate cancer.
-
SN38-(PEG)2-Pom-α
0 ImagesCat. No.: HY-180555SN38-(PEG)2-Pom-α is a selective PROTAC RPL15 degrader. SN38-(PEG)2-Pom-α induces ubiquitin-mediated degradation of RPL15 without affecting TOP1. SN38-(PEG)2-Pom-α induces damage-associated molecular pattern (DAMP) secretion from cancer cells, which activated cGAS-STING signaling in dendritic cells. SN38-(PEG)2-Pom-α enhances anti-PD-1 immunotherapy in a murine melanoma tumor model expressing human CRBN. SN38-(PEG)2-Pom-α can be used for melanoma research.
-
PROTAC BRAF-V600E degrader-2
0 ImagesCat. No.: HY-137488CAS No.: 2417296-82-1PROTAC BRAF-V600E degrader-2 (compound 12) is a potent BRAF-V600E degrader with Kds of 14.4 nM and 9.5 nM for BRAF and BRAF-V600E, respectively. PROTAC BRAF-V600E degrader-2 selectively degraded the kinase domain of BRAF-V600E but not the wild-type BRAF. PROTAC BRAF-V600E degrader-2 inhibits melanoma cell growth.
-
ZXH-4-137
0 ImagesCat. No.: HY-132862CAS No.: 2711006-74-3ZXH-4-137 is a CRBN PROTAC degrader. ZXH-4-137 brings CRBN and VHL E3 ligase into proximity, induces CRBN ubiquitination and proteasomal degradation, and exhibits high selectivity for CRBN. ZXH-4-137 blocks the degradation of CRBN-dependent target proteins such as GSPT1 and CDK9. ZXH-4-137 serves as a chemical knockdown tool compound for investigating CRBN-dependent biological processes.
-
PROTAC RET Degrader 1
0 ImagesCat. No.: HY-178964CAS No.: 2760847-82-1PROTAC RET Degrader 1 (Compound 20) is an orally active and blood-brain barrier-crossing RET PROTAC degrader with DC50 values for RET (WT), RET (G810S), RET (G810C), and RET (G810R) of 1.7, 3, 12, and 21 nM, respectively. PROTAC RET Degrader 1 exhibits potent anti-proliferative activity in cancer cell lines carrying oncogenic RET fusions (such as KIF5B-RET, CCDC6-RET) or mutations (such as RET (C634W)). PROTAC RET Degrader 1 shows significant anti-tumor activity in human tumor xenograft (PDX) mouse models. PROTAC RET Degrader 1 can be used for the study of RET-positive cancers Pink: RET ligand (HY-179308); Blue: CRBN ligand (HY-179307); Black: Linker).
-
MS5033
0 ImagesCat. No.: HY-143882CAS No.: 2376137-29-8MS5033 is a potent PROTAC-based AKT (protein kinase B) degrader, with a DC50 of 430 nM in PC3 cells.
-
R4VPL3-1
0 ImagesCat. No.: HY-184506R4VPL3-1 is a PROTAC-like degrader that simultaneously targets RNF4 and VHL, and also acts as a ferroptosis inducer. R4VPL3-1 induces iron-dependent lipid peroxidation and ferroptosis-mediated rapid cell death in cancer cells. R4VPL3-1 is applicable to research on human melanoma, human cutaneous squamous cell carcinoma, metastatic human sarcoma, malignant peripheral nerve sheath tumor, pigmented villonodular synovitis, undifferentiated pleomorphic sarcoma, myxofibrosarcoma, and lung adenocarcinoma.
-
PROTAC EZH2 Degrader-19
0 ImagesCat. No.: HY-181320CAS No.: 2653338-65-7PROTAC EZH2 Degrader-19 (compound 6) is a is a PROTAC protein degrader targeting EZH2 with an IC50 of 15.00 nM. PROTAC EZH2 Degrader-19 induces strong degradation of all PRC2 subunits (EZH2, SUZ12, EED, RbAp48) in a concentration- and time-dependent manner.PROTAC EZH2 Degrader-19 exhibits antiproliferative effects in cancer cells.PROTAC EZH2 Degrader-19 can be used for the research of cancer.
-
cis-VZ185
0 ImagesCat. No.: HY-114322ACAS No.: 2306193-98-4cis-VZ185 serves as a non-degradative control and inactive analog of VZ185 (HY-114322), a dual-target BRD7/BRD9 degrader PROTAC. cis-VZ185 exerts antiproliferative activity against epithelioid sarcoma cells only at high concentrations. cis-VZ185 induces morphological changes in osteosarcoma cells. cis-VZ185 can be used in studies related to epithelioid sarcoma.
-
MPD2
0 ImagesCat. No.: HY-162464MPD2 is a Cereblon (CRBN) ligand and SARS-CoV-2 MPro degrader with an IC50 <1000 nM against SARS-CoV-2 MPro[1]. MPD2 engages CRBN to mediate ubiquitination and proteasomal degradation of SARS-CoV-2 MPro, reducing SARS-CoV-2 MPro protein levels in infected cells. MPD2 inhibits viral replication of various SARS-CoV-2 strains and acts against nirmatrelvir-resistant SARS-CoV-2 viruses. MPD2 can be used for the research of covid-19 and for fighting against drug-resistant viral variants..
-
XF056-132
0 ImagesCat. No.: HY-150400ACAS No.: 2694057-55-9Synonyms: MS132N TFAXF056-132 (MS132N TFA) is an inactive WDR5 PROTAC degrader with a Kd value of 106 nM against human targets, and exhibits no significant binding to the VHL complex, serves as a negative control for MS132. XF056-132 binds to WDR5, does not induce WDR5 degradation in pancreatic cancer cells, and exerts no inhibitory effect on adenocarcinoma cells. XF056-132 can be used in the research of pancreatic ductal adenocarcinoma.
-
PROTAC VEGFR-2 degrader-1
0 ImagesCat. No.: HY-146368CAS No.: 2601594-19-6
-
PROTAC SMARCA2/4 degrader-8
0 ImagesCat. No.: HY-159460CAS No.: 2568507-14-0
-
PROTAC HPK1 Degrader-7
0 ImagesCat. No.: HY-179727PROTAC HPK1 Degrader-7 (compound D02) is a potent and selective PROTAC HPK1 degrader with an DC50 of 3.07 nM. PROTAC HPK1 Degrader-7 exhibits selectivity over GLK. PROTAC HPK1 Degrader-7 induces HPK1 degradation in a CRBN- and proteasome-dependent manner. PROTAC HPK1 Degrader-7 inhibits SLP-76 phosphorylation, induces IL-2 and IFN-γ secretion in human primary T cells. PROTAC HPK1 Degrader-7 can be used for immunology research.
-
PROTAC WDR5 degrader 1
0 ImagesCat. No.: HY-168487CAS No.: 2737222-94-3PROTAC WDR5 degrader 1 is a heterobifunctional WDR5 PROTAC degrader with a DC50 value of 53 nM and a Kd value of 18 nM, exhibiting selective WDR5 degradation activity and cell permeability. PROTAC WDR5 degrader 1 induces proliferation defects in leukemia cells, with enhanced efficacy in cells overexpressing VHL. PROTAC WDR5 degrader 1 is applicable to research related to acute myeloid leukemia.
-
PROTAC TSSK1 Degrader-2
0 ImagesCat. No.: HY-184464PROTAC TSSK1 Degrader-2 is a cereblon-recruiting PROTAC degrader targeting TSSK1, with a DC50 of 10.8 nM and an IC50 of 56.8 nM against TSSK1. PROTAC TSSK1 Degrader-2 recruits the cereblon E3 ubiquitin ligase to induce proteasomal degradation of TSSK1. PROTAC TSSK1 Degrader-2 reduces the motility and in vitro fertilization capacity of mouse sperm. PROTAC TSSK1 Degrader-2 undergoes metabolic N-dealkylation and exhibits high efflux. PROTAC TSSK1 Degrader-2 can be used in studies related to male fertility.
-
PROTAC erf3a Degrader-2
0 ImagesCat. No.: HY-163938ACAS No.: 3033871-15-4PROTAC erf3a Degrader-2 (Compound C59) is an orally active PROTAC erf3a Degrader. PROTAC erf3a Degrader-2 inhibits protein expression of SRD5A3 and GSPT1(eRF3a). PROTAC erf3a Degrader-2 inhibits cancer cell proliferation (eg: 22Rv1). PROTAC erf3a Degrader-2 can be used for research of prostate cancer, ovarian cancer, liver cancer, cervical cancer, leukemia, breast cancer.
